A new non-invasive approach for early classification of renal rejection types using diffusion-weighted MRI

Author(s):  
Mohamed Shehata ◽  
Fahmi Khalifa ◽  
Elizabeth Hollis ◽  
Ahmed Soliman ◽  
Ehsan Hosseini-Asl ◽  
...  
1999 ◽  
Vol 9 (9) ◽  
pp. 1916-1918 ◽  
Author(s):  
C. Debaere ◽  
T. Stadnik ◽  
M. De Maeseneer ◽  
M. Osteaux

2016 ◽  
Vol 2 (6) ◽  
pp. 309
Author(s):  
Michelle Leech ◽  
John Gaffney ◽  
Laure Marignol

Prostate cancer represents 11% of all cancers in the European Union and 9% of all cancer deaths. Standard MRI for prostate cancer includes high-resolution T2-weighted images, which allow for the assessment of the prostate and the tumour, as tumours arising from the peripheral zone appear dark compared to the expected normally bright peripheral gland tissue. Over the past number of years, the application of diffusion-weighted MRI (DW-MRI) has progressed to include both diagnostic and prognostic roles in oncology. DW-MRI images should be analysed together with the T2-weighted images and the corresponding apparent diffusion coefficient (ADC) maps. We searched PubMed, Cochrane, and Science Direct for relevant journal articles and reviews published up until April 2015 using the search terms “functional MRI” OR “multiparametric MRI” OR “MRSI” AND “diagnosis” AND “prostate cancer” OR “prostate”. The literature indicates that DW-MRI is an important parameter in the identification of prostate cancer. It has the ability to improve sensitivity and specificity, relative to T2-weighted images alone, and has been demonstrated to correlate with tumour grade.


2001 ◽  
Vol 37 ◽  
pp. S341
Author(s):  
M.R. Pfeffer ◽  
R. Spiegelman ◽  
U. Nisim ◽  
Y. Roth ◽  
S.E. Maier ◽  
...  

eLife ◽  
2018 ◽  
Vol 7 ◽  
Author(s):  
Ian F Harrison ◽  
Bernard Siow ◽  
Aisha B Akilo ◽  
Phoebe G Evans ◽  
Ozama Ismail ◽  
...  

The glymphatics system describes a CSF-mediated clearance pathway for the removal of potentially harmful molecules, such as amyloid beta, from the brain. As such, its components may represent new therapeutic targets to alleviate aberrant protein accumulation that defines the most prevalent neurodegenerative conditions. Currently, however, the absence of any non-invasive measurement technique prohibits detailed understanding of glymphatic function in the human brain and in turn, it’s role in pathology. Here, we present the first non-invasive technique for the assessment of glymphatic inflow by using an ultra-long echo time, low b-value, multi-direction diffusion weighted MRI sequence to assess perivascular fluid movement (which represents a critical component of the glymphatic pathway) in the rat brain. This novel, quantitative and non-invasive approach may represent a valuable biomarker of CSF-mediated brain clearance, working towards the clinical need for reliable and early diagnostic indicators of neurodegenerative conditions such as Alzheimer’s disease.


2021 ◽  
Author(s):  
F. Serpi ◽  
S. Gitto ◽  
M. Bologna ◽  
I. Emili ◽  
D. Albano ◽  
...  

Sensors ◽  
2020 ◽  
Vol 20 (5) ◽  
pp. 1539 ◽  
Author(s):  
Chris Dulhanty ◽  
Linda Wang ◽  
Maria Cheng ◽  
Hayden Gunraj ◽  
Farzad Khalvati ◽  
...  

Prostate cancer is the most commonly diagnosed cancer in North American men; however, prognosis is relatively good given early diagnosis. This motivates the need for fast and reliable prostate cancer sensing. Diffusion weighted imaging (DWI) has gained traction in recent years as a fast non-invasive approach to cancer sensing. The most commonly used DWI sensing modality currently is apparent diffusion coefficient (ADC) imaging, with the recently introduced computed high-b value diffusion weighted imaging (CHB-DWI) showing considerable promise for cancer sensing. In this study, we investigate the efficacy of ADC and CHB-DWI sensing modalities when applied to zone-level prostate cancer sensing by introducing several radiomics driven zone-level prostate cancer sensing strategies geared around hand-engineered radiomic sequences from DWI sensing (which we term as Zone-X sensing strategies). Furthermore, we also propose Zone-DR, a discovery radiomics approach based on zone-level deep radiomic sequencer discovery that discover radiomic sequences directly for radiomics driven sensing. Experimental results using 12,466 pathology-verified zones obtained through the different DWI sensing modalities of 101 patients showed that: (i) the introduced Zone-X and Zone-DR radiomics driven sensing strategies significantly outperformed the traditional clinical heuristics driven strategy in terms of AUC, (ii) the introduced Zone-DR and Zone-SVM strategies achieved the highest sensitivity and specificity, respectively for ADC amongst the tested radiomics driven strategies, (iii) the introduced Zone-DR and Zone-LR strategies achieved the highest sensitivities for CHB-DWI amongst the tested radiomics driven strategies, and (iv) the introduced Zone-DR, Zone-LR, and Zone-SVM strategies achieved the highest specificities for CHB-DWI amongst the tested radiomics driven strategies. Furthermore, the results showed that the trade-off between sensitivity and specificity can be optimized based on the particular clinical scenario we wish to employ radiomic driven DWI prostate cancer sensing strategies for, such as clinical screening versus surgical planning. Finally, we investigate the critical regions within sensing data that led to a given radiomic sequence generated by a Zone-DR sequencer using an explainability method to get a deeper understanding on the biomarkers important for zone-level cancer sensing.


2021 ◽  
pp. 110050
Author(s):  
Yusuf Kenan Cetinoglu ◽  
Ilker Ozgur Koska ◽  
Muhsin Engin Uluc ◽  
Mustafa Fazil Gelal

Sign in / Sign up

Export Citation Format

Share Document